Mechanistic target of rapamycin (mTOR) within the FKBP12–mTOR complex (mTOR/FKBP12)

The mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine-protein kinase that serves as a master regulator of cellular metabolism, growth, and survival in response to environmental cues such as nutrients and growth factors (UniProt P42345). The specific target "mTOR within the FKBP12–mTOR complex" refers to the allosteric site formed when the intracellular protein FKBP12 binds to rapalogs, such as sirolimus, to inhibit mTOR Complex 1 (mTORC1) (PubMed: 12150925). This ternary complex formation sterically blocks the phosphorylation of downstream substrates like 4E-BP1 and S6K1, which are critical for protein translation and cell cycle progression (StatPearls: NBK537184). Dysregulation of this signaling node is a hallmark of various malignancies and genetic disorders, including tuberous sclerosis and lymphangioleiomyomatosis (PubMed: 31036603). Consequently, targeting this complex is a well-established therapeutic strategy for both oncology and the prevention of organ transplant rejection (NIH: NCT00002844). However, because mTOR is central to many physiological processes, its inhibition can lead to significant side effects, including metabolic disturbances and impaired tissue repair (PubMed: 29673311).

Other names

FKBP12-rapamycin-binding domainFRB domain of mTORMammalian target of rapamycinFK506-binding protein 12 - mTOR complexFRAPRAFT1RAPT1

Allosteric inhibition of mTOR Complex 1 (mTORC1) through the formation of a ternary complex between the drug, the immunophilin FKBP12, and the FKBP12-rapamycin-binding (FRB) domain of mTOR, which sterically hinders substrate access to the kinase active site (PubMed: 12150925).